Low bone mineral density as a risk factor for osteoporosis and ways of its correction in male patients with ankylosing spondylosis
https://doi.org/10.14412/1996-7012-2014-3-45-50
Abstract
Objective: to estimate bone mineral density (BMD) in men with ankylosing spondylosis (AS).
Subjects and methods. Seventy-two male patients (mean age 43.2±9.1 years) diagnosed with extended- or late-stage AS (according to the 1984 modified New York criteria) (a study group) were followed up. A control group consisted of 70 apparently healthy men of the same age (46.7±1.9 years) with neither a history of bone fractures and no complains about osteoporosis (OP). In the study and control groups, BMD was determined by dual-energy X-ray absorptiometry.
Results. The patients with AS were found to have statistically significantly lower BMD in the femoral neck and lumbar spine. In the study group, osteopenic syndrome (OPS) was identified in 44 (61.1%): osteopenia (OPe) in 16 (22.2%) and OP in 28 (38.9%). In the control group, OPS was detected in 16 (21.62%) patients, OPe in 12 (16.21%), and OP in 4 (5.40%). Lower BMD was noted in both the femoral neck and lumbar spine in the extended stage of AS and only in the femoral neck in its late stage.
About the Authors
O. A. Pirogova
Kemerovo State Medical Academy, Kemerovo, Russia 22A, Voroshilov St., Kemerovo 650029
Russian Federation
Russian Federation
T. A. Raskina
Kemerovo State Medical Academy, Kemerovo, Russia 22A, Voroshilov St., Kemerovo 650029
Russian Federation
Russian Federation
M. V. Letaeva
Kemerovo State Medical Academy, Kemerovo, Russia 22A, Voroshilov St., Kemerovo 650029
Russian Federation
Russian Federation
References
1. Беневоленская ЛИ, Лесняк ОМ. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Москва. 2011. 272 с. [Benevolenskaya LI, Lesnyak OM. Osteoporoz. Diagnostika, profilaktika i lechenie. Klinicheskie rekomendatsii [Osteoporosis. Diagnostics, prevention and treatment. Clinical recommendations]. Moscow. 2011. 272 p.]
2. Риггз ЛБ, Мелтон Д. Остеопороз. Этиология, диагностика, лечение. Ленинград: БИНОМ, Невский диалект. 2000. 560 с. [Riggz LB, Melton D. Osteoporoz. Etiologiya, diagnostika, lechenie [Osteoporosis. Etiology, diagnostics, treatment]. Leningrad:BINOM, Nevskii dialekt. 2000. 560 p.]
3. NIH Consensus Development Conferenceon Osteoporosis: Prevention, Diagnosis and Therapy. JAMA. 2000;287:785–95.
4. Дыдыкина ИС, Алексеева ЛИ. Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение. Научно-практическая ревматология. 2011;(5):13–7. [Dydykina IS, Alekseeva LI. Osteoporoz pri revmatoidnom artrite: diagnostika, faktory riska, perelomy, lechenie. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(5):13–7. (In Russ.)].
5. DOI: http://dx.doi.org/10.14412/1995-4484- 2011-1454.
6. Ward DD. Health related quality in ankylosing spondylitis: a surveyof 175 patients. Arthritis Care Res. 1999;11(4):247–55. DOI: http://dx.doi.org/10.1002/1529- 0131(199908)12:4%3C247::AIDART3%3E3.0.CO;2-H.
7. Волнухин ЕВ, Галушко ЕА, Бочкова АГ и др. Клиническое многообразие анкилозирующего спондилита в реальной практике врача-ревматолога в России (чаcть 1). Научно-практическая ревматология. 2012;50(2):44–9. [Volnukhin EV, Galushko EA, Bochkova AG, et al. Clinical diversity of ankylosing spondylitis in the real practice of a rheumatologist in Russia (Part 1). Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(2):44–9. (In Russ.)]. DOI: ttp://dx.doi.org/10.14412/1995-4484-2012-1272.
8. Braun J. Epidemiology and prognostic aspects of ankylosing spondylitis. Radiologe. 2004;44(3):209–10,212–6. DOI: http://dx.doi.org/10.1007/s00117-004-1025-9.
9. Фоломеева ОМ, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008;(4):4–13. [Folomeeva OM, Galushko EA, Erdes ShF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;(4):4–13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484- 2008-529.
10. Насонов ЕЛ, Скрипникова ИА, Насонова ВА. Проблема остеопороза в ревматологии. Москва: Стин; 1997. 778 с. [Nasonov EL, Skripnikova IA, Nasonova VA. Problema osteoporoza v revmatologii [Osteoporosis problem in rheumatology]. Moscow: Stin; 1997. 778 p.] 10. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):335–9. DOI: http://dx.doi.org/10.1097/BOR.0b013e328133f5b3.
11. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90. DOI: http://dx.doi.org/10.1016/S0140- 6736(07)60635-7.
12. Bessant R, Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol. 2002;29(7):1511¬9.
13. Lange U, Kluge A, Strunk J. Ankylosing spondylitis and bone mineral density – what is the ideal tool for measurement. Rheumatol Int. 2005;26(2):115–20. Epub 2004 Nov 5.
14. Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am. 2006;32(4):631–58. DOI: http://dx.doi.org/ 10.1016/j.rdc.2006.07.002.
15. Sivri A, Kiling S, Gokce-Kutsal Y, Ariyurek M. Bone mineral density in ankylosing spondylitis. Clin Rheumatol. 1996;15(1):51–4. DOI: http://dx.doi.org/10.1007/BF02231685.
16. Devogelaer JP, Maldague В, Malghem J, Deuxchaisnes CN. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plane radiographs with single- and dualphoton absorptiometry and with quantitative computed tomography. Arthritis Rheum. 1992;35(9):1062–7. DOI: http://dx.doi.org/10.1002/art.1780350911.
17. Meirelles ES, Borelli А, Camargo OP. Influenceof disease activity andchronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 1999;18(5):364–8. DOI: http://dx.doi.org/10.1007/s100670050120.
18. Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic riteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361. DOI: http://dx.doi.org/10.1002/art.1780270401.
19. Capaci K, Hepguler S, Argin M, Tаs I. Bone minerаl density in mild аnd аdvаncedwith аnkylosing spondylitis. Yonsei Med J. 2003;44(3):379–84.
20. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphoshonates on the osteoclast mevalonate pathway. Endocrinology. 2000;14(12):4793–6. DOI: http://dx.doi.org/10.1210/endo.141.12.7921.
21. Rogers MJ. New insights into the molecular mechanisms of action of bisphoshonates. Curr Pharm Des. 2003;9(32):2643–58. DOI: http://dx.doi.org/10.2174/1381612033453640.
22. Раскина ТА, Летаева МВ. Гендерные особенности остеопенического синдрома в зависимости от активности ревматоидного воспаления. Современная ревматология. 2010;(3):28–33. [Raskina TA, Letaeva MV. Gender peculiarities of the osteopenic syndrome in the dependence on the rheumatoid inflammation activity. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2010;(3):28–33. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012- 2010-616.
23. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, rindomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9(5):461–8. DOI: http://dx.doi.org/10.1007/PL00004171.
24. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. Fit research group. J Clin Endocrinol Metab. 2000;85(11):4118–24. DOI:http://dx.doi.org/10.1210/jcem.85.11.6953.
25. Bone HG, Hosking D, Devogelaer JP, et al. Ten year’s experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99. DOI: http://dx.doi.org/10.1056/NEJMoa030897.
26. Торопцова НВ. Остеопороз: взгляд на проблему диагностики и лечения. Современная рематология. 2009;(3):68–72. [Toroptsova NV. Osteoporosis: a view of the problem of diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009;(3):68–72 (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2009-562.
27. Рожинская ЛЯ, Дзеранова ЛК, Марова ЕИ и др. Результаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом (алендронатом). Остеопороз и остеопатии. 1998;(2):28–32. [Rozhinskaya LYa, Dzeranova LK, Marova EI, et al. Results of treatment of post-menopausal osteoporosis bisfosfonaty fosamaksy (alendronaty). Osteoporoz i osteopatii. 1998;(2):28–32. (In Russ.)]
28. Скрипникова ИА, Косматова ОВ. Результаты длительного лечения постменопаузального остеопороза бисфосфонатом – фосамаксом. Остеопороз и остеопатии. 2004;(1):16–9. [Skripnikova IA, Kosmatova OV. Results of long treatment of post-menopausal osteoporosis the bisfosfonaty – fosamaksy. Osteoporoz i osteopatii. 2004;(1):16–9. (In Russ.)]
29. Баркова ТВ, Беневоленская ЛИ, Бакулин АВ. Изучение эффективности и переносимости препарата фосамакс у женщин с постменопаузальным остеопорозом по сравнению с плацебо. Остеопороз и остеопатии. 1998;(2):33–6. [Barkova TV, Benevolenskaya LI, Bakulin AV. Studying of efficiency and shipping of a preparation fosamaks at women with post-menopausal osteoporosis in comparison with placebo. Osteoporoz i osteopatii. 1998;(2):33–6. (In Russ.)]
30. Торопцова НВ, Никитинская ОА. Лечение остеопороза: клинический опыт применения дженерического препарата. Современная рематология. 2011;(1):28–32. [Toroptsova NV, Nikitinskaya OA. Тreatment of osteoporosis: clinical experience in using a generic dru. Sovremennaya revmatologiya =Modern Rheumatology Journal. 2011;(1):28–32. (In Russ.)]
31. Geza B. Vizsgalatok a genericus alendronat natriummal, a sedronnal. Praxis. 2008;17:731–41.
32. Торопцова НВ, Никитинская ОА. Реальная клиническая практика: насколько оправдано назначение генериков. Consilium medicum. Приложение Неврология и ревматология. 2010;(2):42–5. [Toroptsova NV, Nikitinskaya OA. Real clinical practice: purpose of generics is how justified. Consilium medicum. Prilozhenie Nevrologiya i revmatologiya. 2010;(2):42–5. (In Russ.)]
33. Добровольская ОВ, Никитинская ОА, Торопцова НВ. Остеопороз и его осложнения: приверженность лечению и возможности ее повышения. Современная рематология. 2011;(3):30–3. [Dobrovol'skaya OV, Nikitinskaya OA, Toroptsova NV. Osteoporosis and its complications: treatment adherence and possibilities of its enhancement. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011;(3):30–3. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2011-681.
34. Скрипникова ИА, Косматова ОВ, Новиков ВЕ и др. Результаты открытого многоцентрового исследования эффективности и переносимости Фосамакса 70 мг 1 раз в неделю при постменопаузальном остеопорозе. Остеопороз и остеопатии. 2005;(3):34–7. [Skripnikova IA, Kosmatova OV, Novikov VE, et al. Results of open multicenter research of efficiency and Fosamaks's shipping of 70 mg once a week at post-menopausal osteoporosis. Osteoporoz i osteopatii. 2005;(3):34–7. (In Russ.)]
Review
For citations:
Pirogova OA, Raskina TA, Letaeva MV. Low bone mineral density as a risk factor for osteoporosis and ways of its correction in male patients with ankylosing spondylosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2014;8(3):45-50. (In Russ.) https://doi.org/10.14412/1996-7012-2014-3-45-50
Views:
1355
Email this article 